Acrivon Therapeutics, Inc.
acrivon.comWhat Do They Do?
Develops cancer drug candidates and protein-based tumor tests designed to match medicines with patients whose tumors are likely to respond.
10-K for FY2025, filed Mar 19, 2026
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 12, 2026
−$18MView ↗
- ▼ −14% (Loss)
- vs −$21M in Q2 FY2025
An added drug target
The older report described preclinical kinase inhibitor programs; the latest adds an internally discovered candidate for another target and advances it through IND-enabling studies.
10-K for FY2022, filed Mar 28, 2023 10-K for FY2025, filed Mar 19, 2026We also have two preclinical drug programs designed to take advantage of our AP3 platform and the ability to predict tumor sensitivity…View ↗
The first of these is directed at WEE1, a critical node in the DDR pathways. WEE1 inhibitors have demonstrated promising anti-tumor…View ↗
The second, equally advanced preclinical program is directed at PKMYT1, a closely related protein serine/threonine kinase also serving…View ↗
In addition, the company is advancing ACR-6840, an internally discovered development candidate targeting CDK11. In preclinical studies…View ↗
Who Do They Compete With?
Competes with Boundless Bio, Sierra Oncology, Sentinel Oncology, Astrazeneca/Merck, Zentalis, Debiopharm, Impact Therapeutics, Shouya Holdings, Aprea, BioCity Biopharma, Wigen Biomedicine Technology, HUYA Biomedicines, Bristol Myers Squibb, Repare Therapeutics, Qilu Pharma, Evariste, and Schrödinger
10-K for FY2025, filed Mar 19, 2026At present, we do not believe we face competition from segments of the pharmaceutical, biotechnology and other related markets that pursue…View ↗
Loading...
